tiprankstipranks
Trending News
More News >
ProQR (PRQR)
NASDAQ:PRQR

ProQR (PRQR) AI Stock Analysis

Compare
1,045 Followers

Top Page

PR

ProQR

(NASDAQ:PRQR)

Rating:49Neutral
Price Target:
$1.50
▼( -10.18% Downside)
ProQR's overall stock score reflects significant challenges in achieving profitability and positive cash flow, despite strong revenue growth. The technical indicators provide some short-term bullish signals, but the longer-term trends remain bearish. The negative P/E ratio highlights valuation difficulties due to ongoing losses, and the absence of a dividend yield limits attractiveness for income investors.
Positive Factors
Market Potential
PRQR's RNA editing therapy, targeting the bile acid transporter for cholestatic diseases, addresses a multi-billion-dollar market, presenting a substantial long-term opportunity.
Technological Advancements
The next-generation AX-0810 has shown a 5.5-fold increase in potency over earlier NTCP EON iterations, along with improved stability in vitro and no evidence of hepatotoxicity or immunostimulatory effects, which indicates a favorable pharmacokinetic, pharmacodynamic, and safety profile.
Negative Factors
Stock Performance
The continued stock decline following a mid-October spike suggests recent market challenges for PRQR.

ProQR (PRQR) vs. SPDR S&P 500 ETF (SPY)

ProQR Business Overview & Revenue Model

Company DescriptionProQR Therapeutics N.V. is a biotechnology company focused on the development of innovative RNA therapies for the treatment of genetic disorders. Headquartered in the Netherlands, ProQR primarily operates within the pharmaceutical and healthcare sectors. The company's core products are based on its proprietary RNA repair platform, which targets genetic mutations at the molecular level to treat rare diseases, with an emphasis on inherited retinal diseases and other genetic conditions.
How the Company Makes MoneyProQR Therapeutics generates revenue through a combination of strategic collaborations, partnerships, and licensing agreements with other pharmaceutical and biotechnology companies. These agreements often involve upfront payments, milestone payments based on the achievement of certain development or regulatory goals, and royalties on future sales of any successfully developed products. Additionally, ProQR may receive funding from government grants and research institutions to support its innovative RNA-based drug development programs. The company's focus on addressing unmet medical needs in rare genetic disorders positions it to potentially benefit from orphan drug designations, which can provide market exclusivity and other financial incentives.

ProQR Financial Statement Overview

Summary
ProQR exhibits strong revenue growth, indicative of expanding operations. However, persistent net losses and negative cash flows highlight financial instability. The balance sheet reflects a relatively healthy leverage position, but the company's path to profitability and positive cash flow remains uncertain.
Income Statement
45
Neutral
ProQR has shown significant revenue growth, increasing from $1.35M in 2021 to $19M in TTM 2025. The gross profit margin is strong, but the company is still operating at a net loss, with net profit margins remaining negative. The EBITDA margin is also negative, indicating challenges in achieving operational profitability.
Balance Sheet
50
Neutral
The debt-to-equity ratio is relatively low, suggesting manageable leverage levels. The equity ratio shows a stable capital structure with a moderate proportion of equity funding. However, the company has been operating with negative net income, impacting return on equity negatively.
Cash Flow
40
Negative
ProQR has faced issues with free cash flow, which has remained negative, impacting its liquidity position. The operating cash flow to net income ratio is unfavorable due to consistent net losses. Despite this, financing activities have provided cash inflows, supporting operational needs.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
19.01M18.91M6.51M4.04M1.35M0.00
Gross Profit
18.29M18.91M6.38M1.56M1.35M-2.19M
EBIT
-33.39M-30.47M-31.86M-64.72M-57.19M-42.37M
EBITDA
-27.17M-24.12M-24.10M-56.46M-54.95M-136.56M
Net Income Common Stockholders
-30.18M-27.76M-28.12M-64.89M-61.68M-46.61M
Balance SheetCash, Cash Equivalents and Short-Term Investments
132.41M149.41M118.92M94.78M187.52M75.84M
Total Assets
151.69M167.96M137.88M171.32M209.58M98.73M
Total Debt
16.85M17.22M19.73M21.97M60.37M34.28M
Net Debt
-115.56M-132.19M-99.19M-72.80M-127.15M-41.56M
Total Liabilities
72.75M79.40M96.49M106.21M96.35M42.18M
Stockholders Equity
78.94M88.56M41.39M65.50M113.83M57.09M
Cash FlowFree Cash Flow
-37.97M-37.81M20.18M-69.22M-26.50M-47.98M
Operating Cash Flow
-37.06M-36.39M21.55M-68.51M-26.01M-47.06M
Investing Cash Flow
13.44M-4.07M4.28M-702.00K-425.00K-924.00K
Financing Cash Flow
70.19M70.28M-2.27M-30.89M136.83M14.50M

ProQR Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1.67
Price Trends
50DMA
1.49
Positive
100DMA
1.89
Negative
200DMA
2.30
Negative
Market Momentum
MACD
0.05
Negative
RSI
54.09
Neutral
STOCH
60.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRQR, the sentiment is Neutral. The current price of 1.67 is above the 20-day moving average (MA) of 1.66, above the 50-day MA of 1.49, and below the 200-day MA of 2.30, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 54.09 is Neutral, neither overbought nor oversold. The STOCH value of 60.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PRQR.

ProQR Risk Analysis

ProQR disclosed 79 risk factors in its most recent earnings report. ProQR reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
Raising additional capital may cause dilution to our existing shareholders. Further, any future financing arrangements, may restrict our operations or require us to relinquish rights to our technologies or product candidates. Q4, 2024
2.
The U.S. Congress, the Trump administration, or any new administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect our business. Q4, 2024

ProQR Peers Comparison

Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
58
Neutral
$123.62M-24.73%-1.02%-8.59%
53
Neutral
$5.14B3.23-45.01%2.85%17.55%-0.69%
52
Neutral
$546.26M-53.82%44.85%
51
Neutral
$135.59M87.50-24.22%-23.40%17.80%
50
Neutral
$211.90M-91.44%-2.04%-478.87%
49
Neutral
$175.70M-52.64%82.38%3.63%
SLSLN
49
Neutral
$238.99M-99.23%-40.10%-16.60%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PRQR
ProQR
1.70
-0.14
-7.61%
CGEN
Compugen
1.45
-1.07
-42.46%
RGLS
Regulus
7.89
5.85
286.76%
TNXP
Tonix Pharma
36.99
-507.01
-93.20%
SLN
Silence Therapeutics
5.06
-17.03
-77.09%
SEER
Seer
2.10
0.22
11.70%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.